IRESS LIMITED — Director's Dealing 2022

Apr 11, 2022

==> picture [82 x 63] intentionally omitted <==

The Manager Company Announcements Office Australian Stock Exchange Exchange Centre 20 Bridge Street SYDNEY NSW 2000

12 April 2022

Dear Manager,

IRESS LIMITED –APPENDIX 3Y – ANDREW WALSH – CEO & MANAGING DIRECTOR

Please find attached an Appendix 3Y announcement relating to Andrew Walsh, CEO & Managing Director.

Yours sincerely

==> picture [137 x 59] intentionally omitted <==

Peter Ferguson Chief Legal Officer & Company Secretary

Iress Limited Corporate Office: Level 16, 385 Bourke Street MELBOURNE VIC 3000 Australia ABN: 47 060 313 359

T +61 3 9018 5800 enquiries@iress.com

www.iress.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Iress Limited
ABN	47 060 313 359

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Andrew Walsh Date of last notice 18 March 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	4 April 2022
No. of securities held prior to change	Ordinary Shares Direct: 476,455 Indirect: 287,168 763,623 Unvested Share/Rights Grants Overview: Deferred Share Rights all Series: 42,736 Performance Rights pre-2019 Series: 91,210

• See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

		Unvested Rights/Grants under revised 2019 executive remuneration framework: Equity Rights: 97,089 Performance Rights: 183,779 Unvested Share/Rights Grants Details: 2018 Series Performance Rights 2018: ● 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: -45,605 ● 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: -45,605 2019 Series Deferred Shares Rights 2019: ● 3 year term, granted 9 May 2019: -42,736 2020 Series– New Framework Performance Rights 2020: ● 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: –80,916 2021 Series- New Framework Equity Rights 2021: ● 2 year term, granted in May 2021, 2 year measurement period commencing 28 Feb 2021 - 28 Feb 2023. Shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 Feb 2023 - 28 Feb 2025) -97,089 Performance Rights 2021: ● 3 year term, granted in May 2021, 3 year measurement period commencing 1 Jan 2021 - 31 Dec 2024: -102,863
Class		Ordinary
Number acquired		Nil
Number disposed		119,475
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		Average price per share $11.87

• See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

	No. of securities held after change		Ordinary Shares Direct: 356,980 Indirect: 287,168 644,148 Unvested Share/Rights Grants Overview: Deferred Share Rights all Series: 42,736 Performance Rights pre-2019 Series: 91,210 Unvested Rights/Grants under revised 2019 executive remuneration framework: Equity Rights: 97,089 Performance Rights: 183,779 Unvested Share/Rights Grants Details: 2018 Series Performance Rights 2018: ● 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: -45,605 ● 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: -45,605 2019 Series Deferred Shares Rights 2019: ● 3 year term, granted 9 May 2019: -42,736 2020 Series– New Framework Performance Rights 2020: ● 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: –80,916 2021 Series- New Framework Equity Rights 2021: ● 2 year term, granted in May 2021, 2 year measurement period commencing 28 Feb 2021 - 28 Feb 2023. Shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 Feb 2023 - 28 Feb 2025) -97,089 Performance Rights 2021: ● 3 year term, granted in May 2021, 3 year measurement period commencing 1 Jan 2021 - 31 Dec 2024: -102,863

• See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Nature of change Disposal of shares to meet normal tax obligations arising from Example: on-market trade, off-market trade, exercise of the vesting of rights. options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 4